Charles Ryan

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint Expression of insulin-like growth factor-1 receptor in local and metastatic prostate cancer
    Charles J Ryan
    Department of Medicine, UCSF Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94115, USA
    Urol Oncol 25:134-40. 2007
  2. doi request reprint A urologic oncology roundtable discussion: how to choose among the available therapies for the treatment of castration-resistant prostate cancer
    Charles Ryan
    Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA
    Postgrad Med 125:114-6. 2013
  3. doi request reprint Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial
    Charles J Ryan
    University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94115, USA
    J Clin Oncol 31:2791-8. 2013
  4. doi request reprint Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone
    Charles J Ryan
    University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94115, USA
    Clin Cancer Res 19:215-24. 2013
  5. pmc Abiraterone in metastatic prostate cancer without previous chemotherapy
    Charles J Ryan
    Genitourinary Medical Oncology Program, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94115, USA
    N Engl J Med 368:138-48. 2013
  6. doi request reprint Abiraterone acetate for the treatment of prostate cancer
    Charles J Ryan
    Genitourinary Medical Oncology, UCSF Helen Diller Family Comprehensive Cancer Center, 1600 Divisadero Street, San Francisco, CA 94115, USA
    Expert Opin Pharmacother 14:91-6. 2013
  7. pmc Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer
    Mark Jesus M Magbanua
    Department of Medicine, Division of Hematology Oncology, University of California San Francisco, USA
    BMC Cancer 12:78. 2012
  8. ncbi request reprint Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study
    Charles J Ryan
    Urologic Oncology Program, University of California, San Francisco, California 94143, USA
    Clin Cancer Res 13:2030-7. 2007
  9. ncbi request reprint Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC)
    Charles J Ryan
    Urologic Oncology Program, UCSF Comprehensive Cancer Center, 1600 Divisadero 3rd Floor, San Francisco, CA, USA
    Invest New Drugs 25:445-51. 2007
  10. ncbi request reprint Initial treatment patterns and outcome of contemporary prostate cancer patients with bone metastases at initial presentation: data from CaPSURE
    Charles J Ryan
    Department of Medicine, University of California at San Francisco Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California 94143, USA
    Cancer 110:81-6. 2007

Research Grants

Detail Information

Publications45

  1. ncbi request reprint Expression of insulin-like growth factor-1 receptor in local and metastatic prostate cancer
    Charles J Ryan
    Department of Medicine, UCSF Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94115, USA
    Urol Oncol 25:134-40. 2007
    ..Despite this targeting, there are conflicting data on the presence of this receptor in human tumor samples, largely because of differences in technique...
  2. doi request reprint A urologic oncology roundtable discussion: how to choose among the available therapies for the treatment of castration-resistant prostate cancer
    Charles Ryan
    Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA
    Postgrad Med 125:114-6. 2013
    ....
  3. doi request reprint Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial
    Charles J Ryan
    University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94115, USA
    J Clin Oncol 31:2791-8. 2013
    ..In this article, we investigate the relationship between baseline serum androgen (SA) levels and OS...
  4. doi request reprint Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone
    Charles J Ryan
    University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94115, USA
    Clin Cancer Res 19:215-24. 2013
    ....
  5. pmc Abiraterone in metastatic prostate cancer without previous chemotherapy
    Charles J Ryan
    Genitourinary Medical Oncology Program, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94115, USA
    N Engl J Med 368:138-48. 2013
    ..We evaluated this agent in patients who had not received previous chemotherapy...
  6. doi request reprint Abiraterone acetate for the treatment of prostate cancer
    Charles J Ryan
    Genitourinary Medical Oncology, UCSF Helen Diller Family Comprehensive Cancer Center, 1600 Divisadero Street, San Francisco, CA 94115, USA
    Expert Opin Pharmacother 14:91-6. 2013
    ..Recent insights suggest that CRPC continues to rely on an active AR pathway for cell survival and growth...
  7. pmc Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer
    Mark Jesus M Magbanua
    Department of Medicine, Division of Hematology Oncology, University of California San Francisco, USA
    BMC Cancer 12:78. 2012
    ..However, it is the molecular characterization of CTCs that offers insight into the biology of these tumor cells in the context of personalized treatment...
  8. ncbi request reprint Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study
    Charles J Ryan
    Urologic Oncology Program, University of California, San Francisco, California 94143, USA
    Clin Cancer Res 13:2030-7. 2007
    ..Ketoconazole is used as an inhibitor of adrenal androgen synthesis in men with androgen-independent prostate cancer. This study analyzes the relationship between pretreatment androgen levels and outcome following ketoconazole treatment...
  9. ncbi request reprint Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC)
    Charles J Ryan
    Urologic Oncology Program, UCSF Comprehensive Cancer Center, 1600 Divisadero 3rd Floor, San Francisco, CA, USA
    Invest New Drugs 25:445-51. 2007
    ..While further study is indicated, careful attention must be paid to the novel toxicities of this agent with prolonged dosing...
  10. ncbi request reprint Initial treatment patterns and outcome of contemporary prostate cancer patients with bone metastases at initial presentation: data from CaPSURE
    Charles J Ryan
    Department of Medicine, University of California at San Francisco Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California 94143, USA
    Cancer 110:81-6. 2007
    ....
  11. ncbi request reprint Prostate specific antigen only androgen independent prostate cancer: natural history, challenges in management and clinical trial design
    Charles J Ryan
    Department of Medicine and University of California San Francisco Comprehensive Cancer Center, University of California San Francisco, San Francisco, California 94143, USA
    J Urol 178:S25-9. 2007
    ..A consensus panel was convened to review data and propose a strategy for trial design and prioritization...
  12. ncbi request reprint Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome
    Charles J Ryan
    Urologic Oncology Program, University of California San Francisco Comprehensive Cancer Center, University of California San Francisco, San Francisco, California 94115, USA
    J Urol 178:2372-6; discussion 2377. 2007
    ..The efficacy of ketoconazole plus the immunostimulatory cytokine granulocyte-macrophage colony-stimulating factor was prospectively evaluated in patients with castration resistant prostate cancer with and without metastases...
  13. doi request reprint A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer
    Charles J Ryan
    Department of Medicine and the corrected UCSF Comprehensive Cancer Center, University of California San Francisco, CA 94143, USA
    BJU Int 101:436-9. 2008
    ....
  14. doi request reprint Inhibitory effects of nordihydroguaiaretic acid (NDGA) on the IGF-1 receptor and androgen dependent growth of LAPC-4 prostate cancer cells
    Charles J Ryan
    Department of Medicine, University of California, San Francisco, California 94143, USA
    Prostate 68:1232-40. 2008
    ..The current study evaluates the effect of NDGA on the androgen-stimulated growth of human prostate cancer cells...
  15. ncbi request reprint The selection of hormonal therapy in prostate cancer: who, when, and for how long?
    Charles J Ryan
    Department of Medicine, UCSF Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero St, San Francisco, CA 94143, USA
    J Natl Compr Canc Netw 2:261-8. 2004
    ....
  16. pmc Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy
    Charles J Ryan
    Urologic Oncology Program, University of California, San Francisco, San Francisco, CA 94115, USA
    J Clin Oncol 28:1481-8. 2010
    ..This phase I dose-escalation study of abiraterone acetate evaluated safety, pharmacokinetics, and effects on steroidogenesis and prostate-specific antigen (PSA) levels in men with CPRC with or without prior ketoconazole therapy...
  17. pmc Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response
    Charles J Ryan
    Genitourinary Medical Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California 94115, USA
    Clin Cancer Res 17:4854-61. 2011
    ....
  18. doi request reprint Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically
    Charles J Ryan
    UCSF Helen Diller Family Comprehensive Cancer Center, 1600 Divisadero St, San Francisco, CA 94115, USA
    J Clin Oncol 29:3651-8. 2011
    ..The clinical success of therapies that directly target androgen synthesis as well as the most common aberrancies of the AR confirm that prostate cancer retains dependence on AR signaling, even in the castrate state...
  19. ncbi request reprint Secondary hormonal manipulations in prostate cancer
    Charles J Ryan
    Urologic Oncology Program, University of California at San Francisco Comprehensive Cancer Center, 1600 Divisadero Street, 3rd Floor, San Francisco, CA 94143, USA
    Curr Oncol Rep 7:228-33. 2005
    ..Collectively, the modest activity of these therapies challenges the notion that advancing prostate cancer will uniformly become "hormone refractory."..
  20. ncbi request reprint Prostate cancer update: 2005
    Charles J Ryan
    Department of Medicine and UCSF Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA
    Curr Opin Oncol 18:284-8. 2006
    ..The purpose of this review is to highlight the most important developments in the diagnosis, prevention, and management of prostate cancer that have been published in the medical literature in the past year...
  21. ncbi request reprint Chemotherapy for hormone-refractory prostate cancer: now it's a question of "when?"
    Charles J Ryan
    UCSF Comprehensive Cancer Center, Box 1711, 1600 Divisadero St, San Francisco, CA 94115, USA
    J Clin Oncol 23:8242-6. 2005
    ..In this review, we will highlight some of the issues that impact on the decision of when to start chemotherapy and in whom as well as the potential benefits of secondary hormonal approaches...
  22. ncbi request reprint Early versus delayed androgen deprivation for prostate cancer: new fuel for an old debate
    Charles J Ryan
    UCSF Comprehensive Cancer Center, 1600 Divisadero St, San Francisco CA 94143, USA
    J Clin Oncol 23:8225-31. 2005
    ..Consideration of AD is therefore warranted early in the clinical course of high-risk patients...
  23. ncbi request reprint Secondary hormonal manipulations in prostate cancer
    Charles J Ryan
    Urologic Oncology Program, UCSF Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94115, USA
    Hematol Oncol Clin North Am 20:925-34. 2006
    ..Novel agents are being developed that seek to prolong the duration of clinical responses and the overall response rate...
  24. ncbi request reprint Progress in detection and treatment of prostate cancer
    Charles J Ryan
    Department of Medicine, UCSF Comprehensive Cancer Center, University of California, San Francisco, California, USA
    Curr Opin Oncol 17:257-60. 2005
    ..The purpose of this review is to highlight the most important developments in the diagnosis, prevention, and management of prostate cancer reported in the past year that have been published in the medical literature...
  25. ncbi request reprint Reduced incidence of bony metastasis at initial prostate cancer diagnosis: data from CaPSURE
    Charles J Ryan
    Department of Medicine, and UCSF Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94143, USA
    Urol Oncol 24:396-402. 2006
    ..This study describes features that characterize patients with M+ compared to those diagnosed with M0 disease...
  26. ncbi request reprint Role of secondary hormonal therapy in the management of recurrent prostate cancer
    Charles J Ryan
    Urologic Oncology Program, University of California San Francisco Comprehensive Cancer Center, University of California San Francisco, San Francisco, California 94143, USA
    Urology 62:87-94. 2003
    ..This article reviews the clinical trial data for these various agents and discusses their role in the management of patients with advanced prostate cancer...
  27. ncbi request reprint High risk biochemical relapse and the timing of androgen deprivation therapy
    Charles J Ryan
    Department of Medicine and UCSF Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero Street, San Francisco, CA 94115, USA
    J Urol 176:S61-5. 2006
    ..We offer guidance on its use in patients with prostate specific antigen recurrence only...
  28. ncbi request reprint The case for secondary hormonal therapies in the chemotherapy age
    Eric J Small
    Urologic Oncology Program, UCSF Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero Street, San Francisco, CA 94115, USA
    J Urol 176:S66-71. 2006
    ..Despite this fact numerous therapies are available that target the interaction of androgen and androgen receptor in the castrate testosterone milieu and many clinical investigations are under way in this area...
  29. ncbi request reprint Androgen deprivation therapy in locally advanced and metastatic prostate cancer
    C J Ryan
    Department of Medicine and UCSF Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA
    Minerva Urol Nefrol 58:119-26. 2006
    ..In virtually all analyses, patients with high-risk features benefited from early AD when compared to deferred therapy. Consideration of AD is therefore warranted early in the clinical course of high-risk patients...
  30. ncbi request reprint Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationale
    Charles J Ryan
    Urologic Oncology Program, UCSF Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94143, USA
    Urol Oncol 24:250-3. 2006
    ..This review will highlight the clinical experience to date with angiogenesis inhibitors in prostate cancer and the ongoing studies...
  31. doi request reprint Abiraterone acetate for castration resistant prostate cancer
    Shreya Shah
    UCSF, Division of Hematology and Oncology, Department of Medicine, 1600 Divisadero St, Box 1711, San Francisco, CA 94115, USA
    Expert Opin Investig Drugs 19:563-70. 2010
    ..The toxicity profile has also been found to be acceptable. Two large Phase III clinical trials are currently open to accrual and will hopefully validate the impressive Phase II data...
  32. ncbi request reprint Five-year outcomes after neoadjuvant chemotherapy and conformal radiotherapy in patients with high-risk localized prostate cancer
    Charles J Ryan
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Urology 64:90-4. 2004
    ..To describe the 5-year outcomes of patients with high-risk localized prostate cancer treated with neoadjuvant estramustine and vinblastine followed by concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT)...
  33. ncbi request reprint Advances in prostate cancer
    Charles J Ryan
    Urologic Oncology Program, UCSF Comprehensive Cancer Center, University of California San Francisco, San Francisco, California 94143, USA
    Curr Opin Oncol 16:242-6. 2004
    ..The purpose of this review is to highlight the most important developments in the diagnosis, prevention, and management of prostate cancer reported in the past year that have been published in the medical literature...
  34. ncbi request reprint Chemotherapy for good-risk germ-cell tumors
    Charles J Ryan
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Joan and Sanford I Weill Medical College of Cornell University, New York, NY 10021, USA
    Semin Urol Oncol 20:244-50. 2002
    ..Bleomycin remains controversial in good-risk germ-cell tumors, but the literature suggests that both E(500)P for four cycles or BE(500)P for three cycles may be considered standard...
  35. ncbi request reprint Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design
    Kathleen W Beekman
    Genitourinary Oncology Service, Division of Hematology Oncology, Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, 48109, USA
    Clin Genitourin Cancer 4:299-302. 2006
    ....
  36. ncbi request reprint Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: an early predictor of relapse or incomplete androgen suppression
    Charles J Ryan
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Urology 68:834-9. 2006
    ..To analyze post-androgen depletion (AD) primary tumors to identify markers of treatment failure because AD does not reduce the probability of prostate-specific antigen (PSA) failure after prostatectomy...
  37. ncbi request reprint A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer
    Amy M Lin
    UCSF Comprehensive Cancer Center, University of California, San Francisco, CA 94115, USA
    Clin Genitourin Cancer 5:323-8. 2007
    ..Imatinib inhibits the platelet-derived growth factor receptor that is expressed in prostate cancer and is synergistic with taxanes in preclinical prostate cancer models...
  38. ncbi request reprint Androgen-response elements in hormone-refractory prostate cancer: implications for treatment development
    Andrew C Hsieh
    Department of Medicine, and UCSF Comprehensive Cancer Center, University of California San Francisco, 94143, USA
    Lancet Oncol 8:933-9. 2007
    ..We discuss the effects of bona-fide downstream targets of the androgen receptor on cellular proliferation, evasion of apoptosis, and angiogenesis, and consider the clinical potential of these targets...
  39. ncbi request reprint Novel therapeutic strategies in development for prostate cancer
    Andrea L Harzstark
    University of California, Department of Medicine, Box 1711, San Francisco, 1600 Divisadero Street, San Francisco, CA 94115, USA
    Expert Opin Investig Drugs 17:13-22. 2008
    ..This review will highlight recent and current studies for many of the promising developments for advanced disease, as well as novel early stage approaches...
  40. ncbi request reprint A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy
    Amy M Lin
    University of California San Francisco, San Francisco, CA 94115, USA
    BJU Int 98:763-9. 2006
    ..East Hanover, NJ, USA), as measured by prostate-specific antigen (PSA) kinetics in men with biochemical relapse of prostate cancer after definitive local therapy...
  41. doi request reprint Therapies in development for castrate-resistant prostate cancer
    Andrea L Harzstark
    Department of Medicine, University of California, San Francisco, 1600 Divisadero Street, Box 1711, San Francisco, CA 94115, USA
    Expert Rev Anticancer Ther 8:259-68. 2008
    ..This review will highlight the promise of these new approaches and the challenges to their development...
  42. doi request reprint Novel concepts in androgen receptor blockade
    Andrew C Hsieh
    The Urologic Oncology Program, UCSF Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94143, USA
    Cancer J 14:11-4. 2008
    ..These include direct androgen receptor inhibitors, inhibitors of adrenal androgen synthesis, and a dual 5alpha-reductase isoenzyme inhibitor...
  43. pmc High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) st
    Christian Langer
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Blood 111:5371-9. 2008
    ..We conclude that high BAALC expression is an independent adverse prognostic factor and is associated with a specific gene-expression profile...
  44. ncbi request reprint Intermittent chemotherapy for metastatic hormone refractory prostate cancer
    Amy M Lin
    UCSF Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94115, USA
    Crit Rev Oncol Hematol 61:243-54. 2007
    ....
  45. ncbi request reprint Innovations and challenges in prostate cancer: summary statement for the 6th Cambridge Conference
    Philip W Kantoff
    Lank Center for Genitourinary Oncology, Boston, Massachusetts, USA
    J Urol 178:S5-8; quiz S4. 2007

Research Grants2